CN Patent

CN1582150A — 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物

Assigned to Novartis AG · Expires 2005-02-16 · 21y expired

What this patent protects

本发明涉及星形孢菌素衍生物在制备用于治疗涉及反常的FLT3受体酪氨酸激酶活性的疾病、尤其是用于治愈和/或预防性治疗白血病和脊髓发育不良综合征的药物中的应用以及治疗涉及反常的FLT3受体酪氨酸激酶活性的疾病的方法。

USPTO Abstract

本发明涉及星形孢菌素衍生物在制备用于治疗涉及反常的FLT3受体酪氨酸激酶活性的疾病、尤其是用于治愈和/或预防性治疗白血病和脊髓发育不良综合征的药物中的应用以及治疗涉及反常的FLT3受体酪氨酸激酶活性的疾病的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN1582150A
Jurisdiction
CN
Classification
—
Expires
2005-02-16
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.